A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

When a GLP-1 drug similar to Ozempic helped slow Parkinson's symptoms A recent New England Journal of Medicine study tested lixisenatide, a GLP-1 drug, as a potential treatment for early-stage ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.